JPS6159290B2 - - Google Patents

Description

[Detailed description of the invention]

The present invention involves heat sterilizing human or cow colostrum (hereinafter referred to simply as colostrum unless otherwise specified) and drying it to remove immunoglobulin, etc. contained in the colostrum. In order to prevent the inactivation of infection-preventing substances due to heating, the colostrum before heat sterilization is injected with monosaccharides, disaccharides, and dextrose equivalent values (hereinafter referred to as
Add one or a mixture of two or more selected from the group of polysaccharide hydrolysates, sugar alcohols, amino acids, sodium salts, and potassium salts with a DE of 15 or more, and uniformly dissolve and disperse. This is a method for producing human or bovine colostrum powder, which is characterized in that it is heated, sterilized, and dried. An object of the present invention is to provide a method of powdering bovine colostrum, which has been hardly used in the past, without impairing the activity of infection-preventing substances as much as possible. Another object of the invention is the treatment of diarrheal diseases in humans or livestock;
The object of the present invention is to provide bovine colostrum powder that can be used for prevention or as a component of feed. Another object of the present invention is to provide a method of powdering human colostrum without damaging infection-preventing substances as much as possible. The aim is to provide human colostrum powder that can give the required amount of human colostrum. Conventionally, antibiotics or other drugs have been used to treat diarrhea in livestock, but these drugs migrate into milk, meat, eggs, etc., making them inconvenient for human consumption. On the other hand, it is known that infectious protective substances such as immunoglobulin, which are contained in high concentrations in bovine colostrum, are effective in preventing or treating diarrhea in livestock, especially calves. (PLIngran et al.: Journal of Pathology
and Bacteriology, Vol. 72, pp. 561-568, 1956 and HW Smith: Journal of Pathology and
Bacteriology, vol. 84, pp. 147-168, 1962). It has also been reported that administering freeze-dried bovine colostrum to infants with refractory diarrhea has a therapeutic effect (LB Fernandez et al.
American Journal of Clinical Nutrition, 26
Vol. 383-384, 1973). Milk expressed within 5 days after calving cannot be used as a raw material for milk or dairy products according to the Ministry of Health and Welfare Ordinance (Ministry of Health and Welfare Ordinance No. 52 of 1952).
It was mainly disposed of either by feeding it to calves or discarding it, and there was no effective way to use it. Bovine colostrum is deep yellow in color, has a foul odor and bitter taste, is highly viscous, and exhibits an acidic reaction. Compared to conventional milk (milk expressed after 6 days after calving), bovine colostrum has a higher solids content, lower lactose and fat content, protein (especially globulin), ash and vitamins (especially High content of vitamin A). Therefore, unlike conventional milk, it is extremely difficult to process bovine colostrum; for example, it is easily coagulated by heat sterilization at 63°C for 30 minutes, so heat sterilization of bovine colostrum has not been carried out in the past. Furthermore, there is no known method for powdering bovine colostrum by spray drying. A few attempts have been made to powderize bovine colostrum in the laboratory by freeze-drying (Hiroshi Kobayashi et al.: Saitama Prefectural Livestock Research Institute Annual Report, 1975 Annual Report, pp. 61-81).
(1977). On the other hand, human colostrum contains large amounts of immunoglobulin, lactoferrin, lysozyme, cellular components, etc., and these infection-preventing substances generally contribute to reducing mortality and morbidity in breast-fed infants. (Takeshi Niki: History of Medicine, Volume 90, 15
~22 pages, 1974). In addition, there is a report that there was no case of intestinal infection or systemic infection in mature newborn infants who ingested only breast milk (Itsuro Yamauchi, Pediatrics, Vol. 27, pp. 119-128, 1974). Furthermore, there are reports that breastfeeding premature infants significantly reduces the incidence of infections caused by intestinal bacteria, such as meningitis, sepsis, and diarrhea (Ikuko Igarashi: Pediatrics, Vol. 28, 392-400) Page, 1975). Generally, breastfed infants ingest milk secreted by their mothers directly from their breasts, but
In some facilities, expressed human milk is stored frozen in a gas-sterilized plastic bag, thawed, warmed, and given to infants before use (Ikuko Igarashi: Pediatric Clinical, Volume 28, pages 392-400,
(1975). In addition, in recent years, it has been reported that heating or gamma irradiation of human milk reduces the immunoglobulin or lactoferrin content (Maria Raptopoulou-Gigi et al., British Medical
Journal, vol. 1, pp. 12-14, 1977, Myron
Liebhaber et al.: Journal of Pediatrics, vol. 91, 897.
~900 pages, 1977 and JEFord et al.: Journal of
Pediatrics, vol. 90, pp. 29-35, 1977). It is known that human colostrum frozen in this way can be given to infants, heat sterilized in the laboratory, or freeze-dried, but it is possible to reduce the deactivation of infection-preventing substances by feeding large quantities of human colostrum. There is no known method of heat sterilizing milk and pulverizing it by freeze-drying or spray-drying. As described above, there have been no attempts to industrially produce and utilize human and bovine colostrum powder in large quantities and at low cost. The present inventors have conducted research on a method to minimize the deactivation of infection-preventing substances contained in colostrum, heat sterilize it, and dry it. One or two selected from the group of monosaccharides, disaccharides, hydrolysates of polysaccharides with a DE of 15 or more, sugar alcohols, amino acids, sodium salts, and potassium salts in amounts specified by the content. The inventors have discovered that by adding the above mixture, it is possible to heat sterilize and dry colostrum, which has been considered difficult in the past, and have completed the present invention. Next, the method of the present invention will be explained in detail. The bovine colostrum used in the method of the present invention is milked within 5 days after calving, and has a titratable acidity (hereinafter referred to as suitable acidity) expressed as lactic acid acidity of 0.6%.
(Weight. The same applies hereafter) The following are desirable. Human colostrum is milk expressed within 5 days after delivery from a healthy mother who is not taking any drugs. Colostrum is transported to a processing plant after milking, but in the case of human colostrum, it is desirable to cool it to 4°C or less before transporting it. The colostrum carried in is passed through a cloth or a purifier to remove dust, and then placed in a storage tank and cooled to about 4° C. or lower while being stirred. Colostrum may be defatted, but if defatted, it is processed using a centrifuge. Next, the solid content of the colostrum is determined by a conventional method (supervised by the Environmental Health Bureau of the Ministry of Health and Welfare: "Food Sanitation Inspection Guidelines by Food", p. 270, March 1970, Japan Food Hygiene Association). And, based on the determined solid content of colostrum, 0.5% or more of monosaccharides, 1% or more of disaccharides, 2% or more of polysaccharide hydrolysates with a DE of 15 or more, and 1% or more of sugars. Alcohol, 0.4% or more of amino acids, 1% or more of sodium salts, and 1% or more of potassium salts are added to colostrum alone, or a mixture of two or more of these is added to colostrum at a ratio of 1% or more. Add and dissolve or disperse to approx. The monosaccharide used in the method of the present invention is commercially available glucose, galactose, fructose or mannose, the disaccharide is commercially available maltose, lactose, sutucarose or lactulose, and the polysaccharide hydrolyzate is commercially available glucose, galactose, fructose or mannose. It is obtained by hydrolyzing polysaccharides with oxygen or acid, and is expressed as the amount of direct reducing sugar expressed as glucose in the hydrolyzate divided by the amount of total solids and multiplied by 100. Supervised by Jiro, "Starch Science Handbook", 291 pages, Asakura Shoten, 1972.
(2013) Commercially available starch syrup, nutritious sugar or soluble polysaccharide with a DE of 15 or more, the sugar alcohol is commercially available inositol, sorbitol, mannitol or maltitol, and the amino acid is:
Commercially available glycine, sarcosine, histidine, serine, lysine or alanine; sodium salts are commercially available sodium citrate, disodium phosphate or trisodium phosphate; potassium salts are commercially available dipotassium phosphate or phosphoric acid. tripotassium acid. In addition, the DE of polysaccharide hydrolyzate is
The reason why it was limited to 15 or more is that DE of less than 15 is difficult to dissolve in colostrum at room temperature. The amounts of these substances (hereinafter simply referred to as stabilizers) were determined from the results of Tests 1 to 7 described below, and amounts less than the above amounts do not have the effect of preventing the deactivation of infection-preventing substances. This is to avoid doing so. The method of adding the stabilizer is not particularly limited, and it may be in the form of a powder or an aqueous solution, but the higher the solid content of the colostrum to be dried, the better the drying efficiency, so it is preferable to add it in the form of a powder. is desirable. The upper limit of the amount of stabilizer added is not particularly limited, but from the viewpoint of minimizing changes in the colostrum powder composition and not producing insoluble stabilizers, 20% of the solid content of colostrum is added. It is desirable to add it in the following proportions. Furthermore, since human colostrum powder is intended for feeding to infants, it contains stabilizers such as glucose, lactulose, lactose, and soluble polysaccharides.
It is desirable to use substances that are conventionally given to infants immediately after birth or used in infant formula.
When adding two or more types of stabilizers at the same time, the types are arbitrarily selected and are not particularly limited, but since amino acids and sugars tend to brown during heat sterilization due to aminocarbonyl reactions, It is desirable not to add both at the same time. The addition of two or more stabilizers can be carried out simultaneously as a mixture or each separately. When a hydrolyzate of a polysaccharide with a DE of 15 or more is added in combination with other stabilizers, the hydrolyzate of the polysaccharide is added to 2% of the colostrum solids content and the other stabilizer is added. It is desirable to add a minimum amount of each curing agent. Also, for example, lactose and lactulose among disaccharides, 2
Various disaccharides may also be added. Next, the colostrum to which the stabilizer has been added is heat sterilized at a temperature and time arbitrarily selected from the range of sterilization temperature of 55 to 75°C and sterilization time of 15 seconds to 60 minutes, and then dried by a conventional method. Ru. In the method of the present invention, the sterilization time and sterilization temperature are limited to 15 seconds to 60 minutes and 55 to 75°C, respectively, because a sufficient sterilization effect cannot be obtained at temperatures below 55°C, even if heated for more than 60 minutes. This is because, at temperatures above 75°C, the denaturation of the infection-preventing substance becomes significant even with short heating, and heating for more than 60 minutes is undesirable in terms of the manufacturing process. In addition, in the method of the present invention, colostrum is heated to sterilize it without inactivating the infection-preventing substances, so for example, the colostrum is heated at 55°C 15°C.
It is impossible to select heating conditions such as seconds or 75°C for 60 minutes. Desirable sterilization conditions are 63℃ for 30 minutes or
70℃ for 1 minute. Drying can be carried out by spraying or freeze-drying, with freeze-drying being preferred from the viewpoint of reducing drying costs. It is desirable to perform spray drying at as low a temperature as possible to prevent the inactivation of the infection-preventing substances.
For example, spray drying can be performed under conditions of a hot air temperature of 150°C and an exhaust air temperature of 70°C. Further, freeze-drying is performed by a conventional method. In the method of the present invention,
Since colostrum with high solids content and viscosity is used,
A concentration process such as spray drying of cow's milk is not necessarily required, but when concentrating, it is desirable to perform it at a low temperature so as not to deactivate the infection-preventing substances. In the manner described above, colostrum powder containing active infection-preventing substances is obtained. Human colostrum powder can be given to infants who require colostrum in the required amount by dissolving it in water or warm water, while bovine colostrum powder can be given to infants who require colostrum in the required amount.
It can be used as a component together with other components, or it can be administered in an appropriate amount as is for treatment. The effects of the method of the present invention are as follows.
Bovine colostrum with high acidity has poor thermal stability, so it has been difficult to heat sterilize it, but it can be easily sterilized by the method of the present invention. Therefore, it becomes possible to collect small amounts of bovine colostrum that is lactated irregularly from a wide area, and the storage conditions for bovine colostrum until milk collection are also relaxed. Further, it is extremely difficult to stably store bovine colostrum in a liquid state at room temperature for a long period of time, but by converting it into powder using the method of the present invention, it becomes easy to store it for a long period of time. Further, there are other advantages such as being able to separate and extract only the active ingredients from the bovine colostrum powder obtained by the method of the present invention. Furthermore, since bovine colostrum can be powdered and stored for a long period of time, bovine colostrum, which has rarely been used in the past, can be used extremely effectively. On the other hand, human colostrum powder produced by the method of the present invention can be stored stably for a long period of time without requiring special equipment such as a freezer, and can be easily transported to a wide range of areas at room temperature. Furthermore, by simply dissolving it in water or warm water, it is possible to easily give the required amount of human colostrum to an infant. Furthermore, by collecting human colostrum from a large number of people to make combined milk, it is possible to reduce individual deviations in the composition of human colostrum, making it possible to feed a large number of infants with human colostrum, which is considered to be extremely important in preventing infection. It has advantages such as being able to be ingested. Next, the method of the present invention will be explained in further detail by showing test examples. [Test 1] Type and amount of sugar added in heating coagulation of bovine colostrum,
The relationship between heating temperature and heating time was tested as follows. The various sugars shown in Table 1 were added at the concentrations shown in Table 1 to the solid content of bovine colostrum (solid content 16.5%) with an appropriate acidity of 0.5%, which was milked within 3 days after calving. , dissolved or dispersed, 63℃, 70
℃ and 75℃, and the time (minutes) until bovine colostrum coagulated was measured. Coagulation was determined as follows. Bovine colostrum after heating was visually observed, and it was determined that it had coagulated if it clearly coagulated or gelled, or if the fluidity was significantly impaired when the container was tilted. A control sample was prepared in the same manner without adding any stabilizer. Furthermore, since starch syrup is in a liquid state, the amount of starch syrup added was expressed in terms of its solid content.

【table】

[Test 2]

The relationship between the type of sugar alcohol, the amount added, the heating temperature, and the heating time on the heating coagulation of bovine colostrum was measured using the same bovine colostrum as in Test 1 and using the same method. The types and amounts of sugar alcohols used in this test are shown in Table 2. The results are shown in Table 2.

【table】

[Test 3]

Test 1 on the relationship between the type of amino acid, amount added, heating temperature, and heating time during heating coagulation of bovine colostrum
It was measured using the same bovine colostrum and using the same method.
The types and amounts of amino acids used in this test are shown in Table 3. The results are shown in Table 3. When amino acids such as glycine were added to bovine colostrum at a rate of 0.4% or more, the coagulation time was observed to be prolonged compared to the control, and the coagulation time was significantly prolonged as the amount added increased.

【table】

[Table] (Note) Unit: Minutes [Test 4] Using the same bovine colostrum as in Test 1, the relationship between the types of sodium and potassium salts, amounts added, heating temperature, and heating time in heating coagulation of bovine colostrum was investigated. Measured using the same method. The types and amounts of sodium and potassium salts used in this test are as follows:
As shown in the table. The results are shown in Table 4. Prolongation of coagulation time was observed for sodium salts such as sodium citrate at 1% or more, and similarly for potassium salts such as dipotassium phosphate at 1% or more, and the coagulation time was significantly prolonged as the amount added increased.

【table】

[Table] (Note) Unit: Minutes [Test 5] Relationship between the amount added, heating temperature, and heating time in heating coagulation of bovine colostrum by mixing two types of stabilizers that were found to be effective in Tests 1 to 4. was measured in the same manner as in Test 1 using the same bovine colostrum. The mixture of stabilizers used in this test, their weight ratios, and amounts added are shown in Table 5. The results are shown in Table 5. In a mixture of equal amounts of glucose and inositol, the coagulation time was observed to be prolonged at 1% or more, and the coagulation time was significantly prolonged as the amount added increased. This trend was similar for mixtures of other two or four stabilizers.

【table】

[Test 6]

Solids content collected within 3 days after calving 13.0%
Using human colostrum, each stabilizer shown in Table 6 was added at each concentration shown in the same table by the same method as Test 1, stirred to dissolve, and incubated at 63°C for 30 minutes and at 70°C for 5 minutes. Heat sterilization was performed for 1 minute. Furthermore, human colostrum to which no stabilizer was added was also treated in the same manner.
The IgA content of these samples was measured, and the percentage of the IgA content in each sample relative to the IgA content of unheated colostrum (control) was calculated.
The survival rate was determined. In addition, the IgA content of human colostrum is
Using the IgA measurement kit manufactured by Behring Institute, the Single Radial Immunodiffusion method (G.
Marcini et al.: Immunochemistry, vol. 2, 235-254.
(Page, 1965). The results are shown in Table 6.

[Test 7]

Solids content expressed within 4 days after calving 18.9
Test 6
Heat sterilization was performed using the same method as above. In addition, bovine colostrum to which no stabilizer was added was also treated in the same manner.

[Table] Miles for measuring IgA content in bovine colostrum
Using an IgA measurement kit manufactured by Laboratories, Single Radial measurement was performed as in the case of human colostrum.
Measurements were performed using the immunodiffusion method. The IgA residual rate was calculated by the same method as Test 6. As is clear from Table 7, in the same way as in the case of human colostrum, in bovine colostrum, various stabilizers can be added to the solid content of bovine colostrum at a specific concentration or higher. Compared to this, the IgA residual rate was higher, and this effect became more pronounced as the concentration increased. In addition, the type and minimum amount of stabilizer that shows the effect of preventing deactivation of bovine colostrum IgA due to heating is from Test 1 to
The results were consistent with the type and minimum amount of the stabilizer that showed an extension of the heating coagulation time of bovine colostrum in Test 4 and the stabilizer that showed the effect of preventing IgA deactivation of human colostrum in Test 6. From the above test results, colostrum contains 0.5% or more of monosaccharides, 1% or more of disaccharides, 2% or more of polysaccharide hydrolysates, 1% or more of sugar alcohols, 0.4% or more of amino acids, based on the solid content of colostrum. By adding one of these at a rate of 1% or more sodium salt and 1% or more potassium salt, or by adding a mixture of two or more types selected from these groups to colostrum at a rate of 1%. It has been revealed that bovine colostrum has the effect of prolonging the coagulation time and preventing the deactivation of infection-preventing substances, and human colostrum has the effect of preventing the deactivation of infection-preventing substances. Example 1 20 kg of human colostrum (solid content 12.5%) collected within 5 days after delivery and stored frozen at -35°C was used. Melt this human colostrum, adjust the temperature to about 4℃, and stir while stirring 25 g of colostrum powder (manufactured by Wako Pure Chemical Industries).
(The amount of lactose added is 1% of the solid content of human colostrum.)
) was added and dissolved. Next, using a stainless steel sterilizer equipped with an agitator, sterilize by holding at 63℃ for 30 minutes, and use an Anhydro Laboratory Spray Dryer (manufactured by Anhydro) equipped with an atomizer CD-63 to reduce the hot air inlet temperature. 180
The mixture was spray-dried under the following conditions: 70°C, exhaust air temperature, and a throughput of 2 kg/hour to obtain about 335 g of human colostrum powder. When the IgA residual rate of this human colostrum powder was measured using the same method as Test 6, it was 83.0%, indicating that there was little deactivation of the infection-preventing substances. Example 2 110 kg of bovine colostrum (solid content 16.4%, titratable acidity 0.45%) milked within 5 days after calving was used. This bovine colostrum was cooled to 5°C, and 5.4 kg of glucose powder (manufactured by Wako Pure Chemical Industries, Ltd.) was gradually added and dissolved while stirring (the amount of glucose added was 30% of the solid content of bovine colostrum). . Next, using a stainless steel sterilizer with a stirrer, the temperature was kept at 70°C for 1 minute to sterilize it, and then processed using a Kästner centrifugal dryer (manufactured by Sawanai Iron Works) with a hot air inlet temperature of 170°C and an exhaust air temperature of 70°C. Spray-dried under the conditions of 120 kg/hour, cow colostrum powder approx.
Obtained 21.8Kg. The IgA residual rate of this bovine colostrum powder was measured in the same manner as Test 7 and was 97.9%, indicating that the inactivation of the infection-protective substance was extremely low. Example 3 2 kg of human colostrum (solid content 13.0%) collected within 5 days after delivery and frozen at -15°C was used.
Melt this human colostrum, adjust the temperature to about 4℃, and while stirring, add 26 g of DE17 soluble polysaccharide powder (manufactured by Toyo Jozo Co., Ltd.) (the amount of soluble polysaccharide to be added is calculated from the solid content of human colostrum ) was added and dissolved. Next, using a stainless steel sterilizer with a stirrer, the human colostrum was sterilized by keeping it at 70°C for 5 hours, and freeze-dried using a freeze dryer (Kyowa Shinku Gigyo Co., Ltd., model RL-50KW) in a conventional manner. Approximately 285 g of powder was obtained.
When the IgA residual rate of this human colostrum powder was measured using the same method as Test 6, it was 76%, indicating that there was little deactivation of the infection-preventing substance. Example 4 5 kg of bovine colostrum (solid content 15.8%, titratable acidity 0.50%) milked within 5 days after calving was used. This bovine colostrum was cooled to 4°C, and while stirring, 40 g of maltitol powder (manufactured by Wako Pure Chemical Industries, Ltd.) was added (the amount of maltitol added was 5% of the solid content of bovine colostrum).
was added and dissolved. Next, using a stainless steel sterilizer with a stirrer,
The mixture was sterilized by being held at 63° C. for 30 minutes, and freeze-dried in a conventional manner using a freeze dryer (Kyowa Shinku Gijutsu Co., Ltd., RL-50KW model) to obtain 825 g of bovine colostrum powder. When the IgA residual rate of this bovine colostrum powder was measured in the same manner as Test 7, it was 84.2%, indicating that there was little deactivation of the infection-preventing substance. Example 5 1 kg of human colostrum (solid content 12.8%) collected within 5 days after delivery and frozen at -35°C was used. Melt this human colostrum, adjust the temperature to about 5℃, and add glucose (manufactured by Wako Pure Chemical Industries, Ltd.), lactulose (manufactured by Morinaga Milk Industry Co., Ltd.), inocyt (manufactured by Wako Pure Chemical Industries, Ltd.) and sodium citrate while stirring. (manufactured by Kanto Kagaku Co., Ltd.) mixed powder (weight ratio 2:1:
1:1) (the total amount of the four types of stabilizers added was 2% of the solid content of human colostrum) was added and dissolved. Next, using a stainless steel sterilizer with a stirrer, it was kept at 63℃ for 30 minutes to sterilize it, and it was freeze-dried using a freeze dryer (Kyowa Shinku Gigyo Co., Ltd., model RL-50KW) in a conventional manner to obtain human colostrum powder. Approximately 130g was obtained. When the IgA residual rate of this human colostrum powder was measured using the same method as in Test 6, it was 87.0%, indicating that there was little deactivation of the infection-preventing substance. Example 6 10 kg of bovine colostrum (solid content 17.5%, titratable acidity 0.35%) milked within 5 days after calving was used. This bovine colostrum was cooled to 5°C, and while stirring, a mixed powder (weight ratio: 1 :1:8) 350g (The total amount of three types of stabilizers was taken as 20% of the solid content of human colostrum)
was added and dissolved. Next, using a stainless steel sterilizer with a stirrer,
Sterilize by holding at 61℃ for 35 minutes and atomizer CD
Bovine colostrum powder was spray-dried using an Anhydro Laboratory Spray Dryer (manufactured by Anhydro) equipped with -63 under the conditions of a hot air inlet temperature of 195°C, an exhaust air temperature of 90°C, and a throughput of 3 kg/hour. Approximately 1.95
Got Kg. Test 7 to check the IgA residual rate of this bovine colostrum powder
When measured using the same method, it was 94.5%,
There was extremely little deactivation of the infection-protecting substances.

Claims (1)

[Scope of Claims] 1. A compound selected from the group of monosaccharides, disaccharides, hydrolysates of polysaccharides having a dextrose equivalent value of 15 or more, sugar alcohols, amino acids, sodium salts and potassium salts in human or cow colostrum. Add one type or a mixture of two or more types and uniformly dissolve or disperse,
A method for producing colostrum powder that prevents the inactivation of infection-preventing substances due to heating, which comprises heat sterilization at a temperature of 55 to 75°C and drying. 2 Monosaccharide, disaccharide, dextrose equivalent value is 15
Hydrolysates of polysaccharides, sugar alcohols,
The colostrum according to claim 1, wherein the amount of the mixture of two or more selected from the group of amino acids, sodium salts, and potassium salts is 1% (weight) or more of the solid content of the colostrum. Powder manufacturing method. 3 The amount of monosaccharides added is 0.5 of the solid content of the colostrum.
% (weight) or more, the method for producing colostrum powder according to claim 1 or 2. 4. The method for producing colostrum powder according to claim 1, 2 or 3, wherein the monosaccharide is glucose, galactose, fructose or mannose. 5 The amount of disaccharides added is 1% of the solid content of the colostrum.
(weight) or more, the method for producing colostrum powder according to claim 1 or 2. 6. The method for producing colostrum powder according to claim 1, 2, or 5, wherein the disaccharide is maltose, lactose, sutucarose, or lactulose. 7 The amount of polysaccharide hydrolyzate with a dextrose equivalent value of 15 or more is 2 of the solid content of the colostrum.
% (weight) or more, the method for producing colostrum powder according to claim 1 or 2. 8. Claims 1, 2, or 7, wherein the hydrolyzate of polysaccharide having a dextrose equivalent value of 15 or more is starch syrup, nutritious sugar, or soluble polysaccharide.
Method for producing colostrum powder as described in section. 9. The method for producing colostrum powder according to claim 1 or 2, wherein the amount of sugar alcohol added is 1% (weight) or more of the solid content of the colostrum. 10. The method for producing colostrum powder according to claim 1, 2, or 9, wherein the sugar alcohol is inositol, sorbitol, mannitol, or maltitol. 11 The amount of amino acids added is equal to the solid content of the colostrum.
The method for producing colostrum powder according to claim 1 or 2, wherein the content is 0.4% (by weight) or more. 12. The method for producing colostrum powder according to claim 1, 2, or 11, wherein the amino acid is glycine, sarcosine, histidine, serine, lysine, or alanine. 13 Claim 1, wherein the amount of sodium salt added is 1% (weight) or more of the solid content of the colostrum.
A method for producing colostrum powder according to item 1 or 2. 14. The method for producing colostrum powder according to claim 1, 2, or 13, wherein the sodium salt is sodium citrate, disodium phosphate, or trisodium phosphate. 15. The method for producing colostrum powder according to claim 1 or 2, wherein the amount of potassium salt added is 1% (weight) or more of the solid content of the colostrum. 16 Claims 1 and 2 in which the potassium salt is dipotassium phosphate or tripotassium phosphate
The method for producing colostrum powder according to item 1 or 15.